Home > Formulary : Adult > Recent Decisions > 2025 >
Decisions 18th March 2025
The following decisions were made at the Joint Formulary Group meeting held on Tuesday 18th March:
New Drug Requests
Oxetacaine and antacid oral suspension (unlicensed) (TLS Red)
-
Approved for radiation induced pharyngitis and/or oesophagitis.
Simvastatin 2% and cholesterol 2% in Unguentum M cream (unlicensed) (TLS Red)
-
Approved for porokeratosis.
5-Fluorouracil injection (unlicensed) (TLS Red)
-
Approved for hypertrophic scarring within the periocular region in patients with impairment of central vision (off-label).
Sodium chloride 5% eyedrops and eye ointment (TLS Amber Specialist Initiated)
-
Approved for corneal oedema.
-
Initial treatment course (usually up to 12 weeks) to be supplied by Eye Hospital. If treatment is required beyond 12 weeks, patients remain in contact with the eye hospital but prescribing can be passed to primary care.
-
Ointment is second line formulation used only where eyedrops are not suitable.
Other discussions/decisions
-
Fenofibrate oral tablets 160mg and capsules 67mg and 200mg for non-proliferative diabetic retinopathy in patients with Type 2 diabetes (off-label). A final decision was not reached by the Group. Fenofibrate to remain non-formulary for non-proliferative diabetic retinopathy while clarification on patient cohorts (based on risk stratification) are reached, and while a pathway for baseline and ongoing blood monitoring is worked through.
-
GLP-1s. The JFG will work with the BNSSG Diabetes Working Group to review the diabetes chapter now the supply situation for GLP-1 RA has largely improved and to implement use of biosimilar GLP-1s.